125 related articles for article (PubMed ID: 7983590)
1. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide.
Lan EL; Ugwu SO; Blanchard J; Fang X; Hruby VJ; Sharma S
J Pharm Sci; 1994 Aug; 83(8):1081-4. PubMed ID: 7983590
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of melanotan II through the ocular route in rabbits.
Pinsuwan S; Myrdal PB; Yalkowsky SH
J Pharm Sci; 1997 Mar; 86(3):396-7. PubMed ID: 9050812
[No Abstract] [Full Text] [Related]
3. Determination of melanotan-II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration.
Mock S; Shen X; Tamvakopoulos C
Rapid Commun Mass Spectrom; 2002; 16(22):2142-7. PubMed ID: 12415547
[TBL] [Abstract][Full Text] [Related]
4. A comparison of HPLC and bioassay methods for plasma melanotan-II (MT-II) determination: application to a pharmacokinetic study in rats.
Ugwu SO; Blanchard J; Nguyen LD; Hadley ME; Dorr RT
Biopharm Drug Dispos; 1994 Jul; 15(5):383-90. PubMed ID: 7981427
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of novel melanogenic drugs. Melanotan-I and -II.
Hadley ME; Hruby VJ; Blanchard J; Dorr RT; Levine N; Dawson BV; al-Obeidi F; Sawyer TK
Pharm Biotechnol; 1998; 11():575-95. PubMed ID: 9760697
[No Abstract] [Full Text] [Related]
6. High-performance liquid chromatographic assay for the alpha-melanotropin[4,10] fragment analogue (Melanotan-II) in rat plasma.
Ugwu SO; Blanchard J
J Chromatogr; 1992 Dec; 584(2):175-80. PubMed ID: 1336500
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I.
Bhardwaj R; Hadley ME; Dorr RT; Dvorakova K; Brooks C; Blanchard J
Pharm Res; 2000 May; 17(5):593-9. PubMed ID: 10888312
[TBL] [Abstract][Full Text] [Related]
8. A glimpse into the underground market of melanotan.
Callaghan Iii DJ
Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142729
[TBL] [Abstract][Full Text] [Related]
9. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review.
Habbema L; Halk AB; Neumann M; Bergman W
Int J Dermatol; 2017 Oct; 56(10):975-980. PubMed ID: 28266027
[TBL] [Abstract][Full Text] [Related]
10. Melanoma associated with the use of melanotan-II.
Hjuler KF; Lorentzen HF
Dermatology; 2014; 228(1):34-6. PubMed ID: 24355990
[TBL] [Abstract][Full Text] [Related]
11. Studies of conformational isomerism in alpha-melanocyte stimulating hormone by design of cyclic analogues.
Nikiforovich GV; Sharma SD; Hadley ME; Hruby VJ
Biopolymers; 1998 Sep; 46(3):155-67. PubMed ID: 9699465
[TBL] [Abstract][Full Text] [Related]
12. Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery.
Kilpeläinen M; Mönkäre J; Vlasova MA; Riikonen J; Lehto VP; Salonen J; Järvinen K; Herzig KH
Eur J Pharm Biopharm; 2011 Jan; 77(1):20-5. PubMed ID: 20965250
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.
Dorr RT; Lines R; Levine N; Brooks C; Xiang L; Hruby VJ; Hadley ME
Life Sci; 1996; 58(20):1777-84. PubMed ID: 8637402
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assay for Melanotan-1 ([Nle4-DPhe7]alpha-melanocyte-stimulating hormone) in biological matrices.
Surendran N; Ugwu SO; Sterling EJ; Blanchard J
J Chromatogr B Biomed Appl; 1995 Aug; 670(2):235-42. PubMed ID: 8548013
[TBL] [Abstract][Full Text] [Related]
15. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.
Dorr RT; Ertl G; Levine N; Brooks C; Bangert JL; Powell MB; Humphrey S; Alberts DS
Arch Dermatol; 2004 Jul; 140(7):827-35. PubMed ID: 15262693
[TBL] [Abstract][Full Text] [Related]
16. Skin pigmentation and pharmacokinetics of melanotan-I in humans.
Ugwu SO; Blanchard J; Dorr RT; Levine N; Brooks C; Hadley ME; Aickin M; Hruby VJ
Biopharm Drug Dispos; 1997 Apr; 18(3):259-69. PubMed ID: 9113347
[TBL] [Abstract][Full Text] [Related]
17. Atypical melanocytic naevi following melanotan injection.
Reid C; Fitzgerald T; Fabre A; Kirby B
Ir Med J; 2013 May; 106(5):148-9. PubMed ID: 23914578
[TBL] [Abstract][Full Text] [Related]
18. Zebrafish Bioassay for Screening Therapeutic Candidates Based on Melanotrophic Activity.
Hong TI; Hwang KS; Choi TI; Kleinau G; Scheerer P; Bang JK; Jung SH; Kim CH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502223
[TBL] [Abstract][Full Text] [Related]
19. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II.
Schulze F; Erdmann H; Hardkop LH; Anemüller W; Rose C; Zillikens D; Fischer TW
Eur J Dermatol; 2014; 24(1):107-9. PubMed ID: 24334249
[No Abstract] [Full Text] [Related]
20. [Melanotan-induced lentigines and nevi].
Thestrup-Pedersen K; Søndergaard K
Ugeskr Laeger; 2011 Mar; 173(13):975. PubMed ID: 21453640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
